

# Improving the diagnostic strategy of patients with recurrent differentiated thyroid cancer with PET/CT.

Gepubliceerd: 10-07-2012 Laatst bijgewerkt: 19-03-2025

N/A

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving tijdelijk gestopt
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Observationeel onderzoek, zonder invasieve metingen

## Samenvatting

### ID

NL-OMON27626

### Bron

Nationaal Trial Register

### Verkorte titel

THYROPET

### Aandoening

Differentiated thyroid cancer

I-124 PET/CT

FDG PET/CT

### Ondersteuning

**Primaire sponsor:** The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital

**Overige ondersteuning:** KWF - The Dutch Cancer Society

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

The number of futile high-dose  $^{131}\text{I}$  treatments that could have been avoided by implementation of pre-therapy imaging based on result of post-therapy scintigraphy.

## Toelichting onderzoek

### Achtergrond van het onderzoek

After initial treatment of DTC patients are followed biochemically by thyroglobulin to detect possible recurrence. Nowadays patients are treated blindly with high dose  $^{131}\text{I}$ . When recurrence is suspected a whole body scintigraphy is made, after blind administration of high dose, 'therapeutic',  $^{131}\text{I}$  to diagnose and treat recurrence and metastatic disease. In up to 50% this strategy can be considered to be futile because they had a negative post-therapeutic whole body scan and/or no objective therapy effect.  $^{124}\text{I}$  in combination with whole body PET became recently available for use in the follow-up of DTC. This could make it possible to more accurately re-stage patients in a whole body procedure, perform dosimetry for subsequent  $^{131}\text{I}$  therapy and predict the outcome of the treatment before the actual treatment with  $^{131}\text{I}$ . Additionally, recurrent DTC lesions that do not accumulate iodine can be re-staged without the futile treatment with  $^{131}\text{I}$ . FDG-PET is able to detect these lesions. The value of FDG-PET before  $^{131}\text{I}$  treatment however has not been tested.

The combination of these two diagnostic tools,  $^{124}\text{I}$ -PET and FDG-PET, has a potential to allow earlier and better restaging and selection for treatment.

The objective is to evaluate the value of combined imaging with  $^{124}\text{I}$ -PET and FDG PET in the prevention of futile treatment with high dose  $^{131}\text{I}$ .

Multicenter prospective observational cohort study.

### Doel van het onderzoek

N/A

### Onderzoeksopzet

N/A

### Onderzoeksproduct en/of interventie

A combination of  $\text{I-124}$  PET/CT and FDG PET/CT to firstly detect the recurrence and secondly assess its biological behavior.

# Contactpersonen

## Publiek

Huispost nummer G04.228<br>UMC Utrecht <br>Postbus 85500  
J.W. Kist  
Utrecht 3508 GA  
The Netherlands  
+31 (0)6 41853004

## Wetenschappelijk

Huispost nummer G04.228<br>UMC Utrecht <br>Postbus 85500  
J.W. Kist  
Utrecht 3508 GA  
The Netherlands  
+31 (0)6 41853004

# Deelname eisen

## Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Patients with a history of differentiated thyroid cancer;
2. After complete thyroidectomy and ablation of functional remnants with 131I;
3. Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml;
4. Ultrasonography of the neck performed < 2 months prior to inclusion.

## Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Age < 18 years;

2. Pregnancy;
3. Incapacitated subjects;
4. Contrast enhanced CT performed < 4 months prior to inclusion;
5. I-131 therapy performed < 12 months prior to inclusion;
6. Indication for other therapy modality (ie. surgery in case of a positive ultrasonography, radiotherapy, embolization or chemotherapy).

## Onderzoeksopzet

### Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

### Deelname

Nederland	
Status:	Werving tijdelijk gestopt
(Verwachte) startdatum:	01-09-2012
Aantal proefpersonen:	100
Type:	Verwachte startdatum

## Ethische beoordeling

Positief advies	
Datum:	10-07-2012
Soort:	Eerste indiening

# Registraties

## Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 38034

Bron: ToetsingOnline

Titel:

## Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

Register	ID
NTR-new	NL3371
NTR-old	NTR3519
CCMO	NL37266.031.11
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON38034

# Resultaten

## Samenvatting resultaten

N/A